Volume 14 Supplement 3
Edited by N Zöllner
Integration of the HIV-1 viral DNA generated by reverse transcription of the RNA genome into the host cell chromosomes is a key step of viral replication, catalyzed by the viral integrase. In October 2007, the...
To review all currently published drug-drug interaction studies with the HIV-integrase inhibitor raltegravir.
Raltegravir is the first integrase inhibitor approved for the treatment of HIV infection based on the superior efficacy it showed compared to optimized backbone therapy alone in patients harboring multidrug re...
Raltegravir, the first approved HIV-1 integrase inhibitor, is able to block the strand transfer step of the HIV proviral DNA integration process into the cellular host DNA. The selected dosage for the pivotal ...
End-stage liver disease has become one of the most frequent causes of death in HIV/HCV-coinfected patients. The role of new antiretrovirals in the progression of liver fibrosis has yet to be defined. However w...
Raltegravir, the first approved integrase inhibitor, has been shown to be virologically effective in Phase II and Phase III clinical trials in both treatment naïve and triple class resistant patients. It also ...
Similar to all antiretroviral drugs, failure of raltegravirbased treatment regimens to fully supress HIV replication almost invariably results in emergence of HIV resistance to this new drug. HIV resistance to...
Citation Impact 2023
Journal Impact Factor: 2.8
5-year Journal Impact Factor: 2.9
Source Normalized Impact per Paper (SNIP): 0.818
SCImago Journal Rank (SJR): 0.736
Speed 2023
Submission to first editorial decision (median days): 36
Submission to acceptance (median days): 151
Usage 2023
Downloads: 1,790,363
Altmetric mentions: 5,415